Edition:
United States

Profile: Neurocrine Biosciences Inc (NBIX.O)

NBIX.O on Nasdaq

79.03USD
17 May 2019
Change (% chg)

$-0.97 (-1.21%)
Prev Close
$80.00
Open
$79.20
Day's High
$79.97
Day's Low
$78.02
Volume
744,148
Avg. Vol
940,311
52-wk High
$126.98
52-wk Low
$64.72

Neurocrine Biosciences, Inc., incorporated on March 20, 1996, is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. The Company's late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist in Phase III development for endometriosis and uterine fibroids that is partnered with AbbVie Inc.; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase (COMT) inhibitor. Its product pipeline also includes NBI-640756 and NBI-74788. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric disease. Its subsidiaries include Neurocrine Continental, Inc., Neurocrine Europe, Ltd. and Neurocrine Therapeutics, Ltd.

The Company's G Protein-Coupled Receptor (GPCR) research platform integrates drug discovery research efforts with a suite of assays and assay systems, and automated analytical techniques. This process, which is also applied to ion channels, provides a profile of pharmacological protein/ligand interactions coupled with in vivo efficacy using discrete animal models allowing movement into preclinical and clinical development.

INGREZZA (valbenazine) - Vesicular Monoamine Transporter 2 Inhibitor (VMAT2)

The Company is developing INGREZZA (valbenazine) to address the unmet medical needs of patients suffering from tardive dyskinesia (TD). INGREZZA causes reversible reduction of dopamine release at the nerve terminal by selectively inhibiting the pre-synaptic VMAT2. INGREZZA may be useful in the treatment of other disorders, such as Huntington's chorea, schizophrenia, Tourette syndrome and tardive dystonia. VMAT2 is a protein concentrated in the human brain that is required for the transmission of nerve impulses between neurons. VMAT2 is responsible for packaging monoamines, such as dopamine, norepinephrine, serotonin and histamine, in neurons.

elagolix – Gonadotropin-Releasing Hormone (GnRH) Antagonist

GnRH is a peptide that stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function. Chronic administration of GnRH agonists is useful in treating hormone-dependent diseases, such as endometriosis and uterine fibroids.

opicapone, Catechol-O-methyltransferase inhibitor

COMT inhibitors are used to prolong the duration of effect of levodopa, which is utilized as a primary treatment option for Parkinson's disease patients. COMT inhibitor is utilized as an adjunct therapy to preparations of levodopa/dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients.

NBI-640756, Essential Tremor

NBI-640756 is a molecule, which is in clinical trials for the treatment of essential tremor. The Company has completed a single site, randomized, double-blind, placebo-controlled sequential dose-escalation, Phase I safety and pharmacokinetics study.

Corticotropin-Releasing Factor (CRF) Receptor1 Antagonist (NBI-74788)

CRF is a hypothalamic hormone released directly into the hypophyseal portal vasculature, which acts on specific CRF1 receptors on corticotropes in the anterior pituitary to stimulate the release of adrenocorticotropin hormone (ACTH). NBI-74788 is a potent, selective, orally-active, non-peptide CRF receptor antagonist as demonstrated in a range of in vitro and in vivo assays. NBI-74788 targets Classic Congenital Adrenal Hyperplasia. It focuses on applying for orphan drug designation for NBI-74788 in the treatment of congenital adrenal hyperplasia.

The Company competes with Myovant Sciences, Inc., Allergan Pharmaceuticals, Inc., AbbVie Inc., Pfizer, Orion Pharma, Hoffman-LaRoche Inc., Sage Therapeutics, Millendo Therapeutics, Teva Pharmaceuticals, Inc. and Lundbeck.

Company Address

Neurocrine Biosciences Inc

12780 El Camino Real
SAN DIEGO   CA   92130-2042
P: +1858.6177600
F: +1858.6177602

Company Web Links